Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
PDA Journal of Pharmaceutical Science and Technology
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
PDA Journal of Pharmaceutical Science and Technology

Advanced Search

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • Follow pda on Twitter
  • Visit PDA on LinkedIn
  • Visit pda on Facebook
Research ArticleConference Proceedings

Proceedings of the 2019 Viral Clearance Symposium, Session 4: Viral Clearance Strategy and Process Understanding

David Roush and Johannes Blümel
PDA Journal of Pharmaceutical Science and Technology July 2022, 76 (4) 323-338; DOI: https://doi.org/10.5731/pdajpst.2021.012680
David Roush
1Bioprocess Development/Biologics Research, Merck & Co., Inc., 2000 Galloping Hill Rd., Kenilworth, NJ, USA; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: david.roush@merck.com
Johannes Blümel
2Division of Virology, Paul-Ehrlich-Institut, Langen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

Abstract

This article describes a summary of discussions and outcomes from the 2019 Viral Clearance Symposium Session 4 on the utilization of knowledge, both from within and external to a given organization (e.g., across the interdisciplinary space), that supports viral clearance strategy and process understanding, including engagement with Health Authorities in the development and implementation. Several significant areas were identified for prioritization in an ICHQ5A update including application of next-generation sequencing (NGS) and replacement of in vivo tests, resin reuse, and use of a parvovirus as a single model virus for virus filtration. Specific opportunities were identified based on case studies for application of prior knowledge to support risk assessments, to guide viral clearance study designs, and to support viral clearance claims based on a limited number of confirmatory runs. One discussion focused specifically on how to apply best practices and prior knowledge to an assessment of the potential impact of resin reuse on viral clearance. Prior experience showed a trend toward larger log reduction values (LRVs) with reused protein A resin. For other resins, differences in LRV (>1.0) between new and reused resins were mainly found when validation was performed in independent studies, not side by side. Another example of applying prior knowledge was an assessment of potential variability and worst-case retrovirus-like particle (RVLP) levels in unprocessed bulk presented by Paul-Ehrlich-Institut. The opportunity to utilize noninfectious surrogates for viruses (such as RVLPs or parvovirus-like particles) in screening experiments to determine the impact of process parameters on viral clearance, and the associated current limitations owing to analytics, was also reviewed.

  • Prior knowledge
  • ICHQ5A
  • Resin reuse
  • Viral clearance
  • © PDA, Inc. 2022
View Full Text

PDA members receive access to all articles published in the current year and previous volume year. Institutional subscribers received access to all content. Log in below to receive access to this article if you are either of these.  

If you are neither or you are a PDA member trying to access an article outside of your membership license, then you must purchase access to this article (below). If you do not have a username or password for JPST, you will be required to create an account prior to purchasing. 

Full issue PDFs are for PDA members only.

Note to pda.org users

The PDA and PDA bookstore websites (www.pda.org and www.pda.org/bookstore) are separate websites from the PDA JPST website. When you first join PDA, your initial UserID and Password are sent to HighWirePress to create your PDA JPST account. Subsequent UserrID and Password changes required at the PDA websites will not pass on to PDA JPST and vice versa. If you forget your PDA JPST UserID and/or Password, you can request help to retrieve UserID and reset Password below.

Log in using your username and password

Forgot your user name or password?

Log in through your institution

You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles

Full issue PDFs are for PDA members only. You can join PDA at www.pda.org. 

PreviousNext
Back to top

In This Issue

PDA Journal of Pharmaceutical Science and Technology: 76 (4)
PDA Journal of Pharmaceutical Science and Technology
Vol. 76, Issue 4
July/August 2022
  • Table of Contents
  • Index by Author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on PDA Journal of Pharmaceutical Science and Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Proceedings of the 2019 Viral Clearance Symposium, Session 4: Viral Clearance Strategy and Process Understanding
(Your Name) has sent you a message from PDA Journal of Pharmaceutical Science and Technology
(Your Name) thought you would like to see the PDA Journal of Pharmaceutical Science and Technology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Proceedings of the 2019 Viral Clearance Symposium, Session 4: Viral Clearance Strategy and Process Understanding
David Roush, Johannes Blümel
PDA Journal of Pharmaceutical Science and Technology Jul 2022, 76 (4) 323-338; DOI: 10.5731/pdajpst.2021.012680

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Proceedings of the 2019 Viral Clearance Symposium, Session 4: Viral Clearance Strategy and Process Understanding
David Roush, Johannes Blümel
PDA Journal of Pharmaceutical Science and Technology Jul 2022, 76 (4) 323-338; DOI: 10.5731/pdajpst.2021.012680
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Session Background and Overview
    • Participants’ Contributions
    • Conclusions
    • Conflict of Interest Declaration
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Proceedings of the 2019 Viral Clearance Symposium: Introduction
  • Proceedings of the 2019 Viral Clearance Symposium, Session 8. Conference Summary: Key Discussion and Outcomes, Pending Questions, and Proposed Experiments and Actions
Show more Conference Proceedings

Similar Articles

Keywords

  • Prior knowledge
  • ICHQ5A
  • Resin reuse
  • Viral clearance

Readers

  • About
  • Table of Content Alerts/Other Alerts
  • Subscriptions
  • Terms of Use
  • Contact Editors

Author/Reviewer Information

  • Author Resources
  • Submit Manuscript
  • Reviewers
  • Contact Editors

Parenteral Drug Association, Inc.

  • About
  • Advertising/Sponsorships
  • Events
  • PDA Bookstore
  • Press Releases

© 2023 PDA Journal of Pharmaceutical Science and Technology ISSN: 1079-7440

Powered by HighWire